News

Sanofi looks to Revolution-ize precision oncology in global SHP2 partnership

"We're enjoying the one-two punch," Mark Goldsmith, president and CEO of Revolution Medicines Inc., told BioWorld after the Redwood City, Calif.-based firm inked an oncology partnership with Sanofi SA covering its SHP2 program. In return for an…

Read more

News

Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program

Less than a year ago, Third Rock startup Revolution Medicines shed its antifungal ambitions and remade itself as an oncology company. Now, the Redwood City-based biotech has apparently wooed Sanofi $SNY into a bang up deal on its first cancer…

Read more

Press Release

Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers

Cambridge, Mass. and Redwood City, CA – July 18, 2018 – Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for…

Read more

News

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation.  

Read more

News

Revolution looks to spin into the clinic with $56M series B

Revolution Medicines Inc. (Revmed) strengthened its balance sheet with a $56 million series B while bolstering its C-suite with a trio of executives. The financing will enable the company to advance its lead SHP2 program through IND and into what…

Read more

News

Revolution Medicines tees up for oncology IND with $56M series B

Revolution Medicines started out in 2014, with a platform that breaks down natural compounds into their composite parts and reassembles them into usable drugs. The company has since zeroed in on oncology and now, with a $56 million round in the bag…

Read more